NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»16/07/2009 [Industry news]
China Biologic Products Hosts its First Forum for Strategy and Development

China Biologic Products, Inc. one of the leading plasma-based pharmaceutical companies in China, today announced that the Company hosted a forum of industry experts on July 10 - 11, 2009, at its headquarters in Taian, Shandong Province, to discuss future development strategies for the Company.

 
China Biologic Products, Inc. one of the leading plasma-based pharmaceutical companies in China, today announced that the Company hosted a forum of industry experts on July 10 - 11, 2009, at its headquarters in Taian, Shandong Province, to discuss future development strategies for the Company. Experts from the bio-pharmaceutical industry included Mr. Zhongwei Zheng, head of the research and development center at the Institute of Blood Transfusion at the Chinese Academy of Medical Science, and Mr. Fengshan Wang, Dean of School of Pharmaceutical Sciences at the Shandong University. Messrs. Zheng and Wang and other domestic and international academics and experts, gathered together to discuss strategies for the development of the new China Biologic, which recently became the largest non-state-owned plasma-based pharmaceutical Company in China following the Companys acquisitions of Dalin Biologic Technologies and also its equity investment in Xian Huitian Blood Products. The forum provided a platform for industry experts to discuss and provide advice to the Company that could create synergies among its subsidiaries including, the initiation of research and development of new drugs, efficient use of resources among the subsidiaries, quality control procedures during collection, production and distribution processes, and other expert opinions to create long term, sustainable growth for the Company. The forum has provided us with many strategic ideas to further the growth of the new China Biologic, said Mr. Chao Ming Zhao, CEO of China Biologic Products: We look forward to implementing some of those strategies and create synergies among our subsidiaries.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.